12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Company News  |  Deals

BioDiem, Changchun BCHT deal

BioDiem granted Changchun exclusive rights to its live attenuated influenza virus (LIAV) technology for an egg-based production method for pandemic and seasonal influenza vaccines for the private market in China. BioDiem's LAIV technology delivers a vaccine through a nasal spray, which eliminates the need for injections. Changchun already has a sublicense to the LAIV technology for the public market in China...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >